Based on the Vertex Pharmaceuticals Inc stock forecast from 22 analysts, the average analyst target price for Vertex Pharmaceuticals Inc is USD 479.32 over the next 12 months. Vertex Pharmaceuticals Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Vertex Pharmaceuticals Inc is Slightly Bullish , which is based on 8 positive signals and 5 negative signals. At the last closing, Vertex Pharmaceuticals Inc’s stock price was USD 492.47. Vertex Pharmaceuticals Inc’s stock price has changed by +0.69% over the past week, -3.77% over the past month and +22.88% over the last year.
No recent analyst target price found for Vertex Pharmaceuticals Inc
No recent average analyst rating found for Vertex Pharmaceuticals Inc
Company Overview Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Read Less
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the tr...Read More
Frequently Asked Questions About Vertex Pharmaceuticals Inc (VRTX) Stock
Based on ratings from 22 analysts Vertex Pharmaceuticals Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 21 buy, 1 sell and 22 hold ratings.
Unfortunately we do not have enough data on VRTX's stock to indicate if its a good dividend stock.
Based on targets from 22 analysts, the average taret price for VRTX is USD 479.32 over the next 12 months. The maximum analyst target price is USD 583 while the minimum anlayst target price is USD 320.
VRTX stock's Price/Earning ratio is 32.57.
Our analysis grades VRTX stock's Price / Earning ratio at F. This means that VRTX stock's Price/Earning ratio is above 78% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this VRTX may be a overvalued for its sector.
The last closing price of VRTX's stock was USD 492.47.
The most recent market capitalization for VRTX is USD 126.52B.
Based on targets from 22 analysts, the average taret price for VRTX is projected at USD 479.32 over the next 12 months.
This means that VRTX's stock price may go down by -2.67% over the next 12 months.
We can't find any ETFs which contains Vertex Pharmaceuticals Inc's stock.
As per our most recent records Vertex Pharmaceuticals Inc has 6,100 Employees.
Vertex Pharmaceuticals Inc's registered address is 50 Northern Avenue, Boston, MA, United States, 02210.
You can get more information about it from Vertex Pharmaceuticals Inc's website at https://www.vrtx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Vertex Pharmaceuticals Inc (VRTX) Stock
Based on ratings from 22 analysts Vertex Pharmaceuticals Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 21 buy, 1 sell and 22 hold ratings.
Unfortunately we do not have enough data on VRTX's stock to indicate if its a good dividend stock.
Based on targets from 22 analysts, the average taret price for VRTX is USD 479.32 over the next 12 months. The maximum analyst target price is USD 583 while the minimum anlayst target price is USD 320.
VRTX stock's Price/Earning ratio is 32.57.
Our analysis grades VRTX stock's Price / Earning ratio at F. This means that VRTX stock's Price/Earning ratio is above 78% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this VRTX may be a overvalued for its sector.
The last closing price of VRTX's stock was USD 492.47.
The most recent market capitalization for VRTX is USD 126.52B.
Based on targets from 22 analysts, the average taret price for VRTX is projected at USD 479.32 over the next 12 months.
This means that VRTX's stock price may go down by -2.67% over the next 12 months.
We can't find any ETFs which contains Vertex Pharmaceuticals Inc's stock.
As per our most recent records Vertex Pharmaceuticals Inc has 6,100 Employees.
Vertex Pharmaceuticals Inc's registered address is 50 Northern Avenue, Boston, MA, United States, 02210.
You can get more information about it from Vertex Pharmaceuticals Inc's website at https://www.vrtx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VRTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
